

# Q3 Interim Report 2021

---

Audiocast at 10:00 am CET  
November 18, 2021



**SCANDION**  
ONCOLOGY

# Disclaimer

---

*This presentation, which should be understood to include these slides, their contents or any part of them, any oral presentation, any question or answer session and any written or oral materials discussed or distributed during a company presentation (the "Presentation"), has been prepared by Scandion Oncology A/S ("Scandion Oncology" or the "Company"), to be used solely for a company presentation. The information contained in the Presentation is provided solely for this purpose.*

*This Presentation does not constitute or form part of, and should not be construed as, any offer, invitation, solicitation or recommendation to purchase, sell or subscribe for any securities in any jurisdiction. The Presentation is intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete disclosure. The Company has not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or under any of the relevant securities laws of any state or other jurisdiction of the United States of America.*

*Certain information contained herein has been obtained from published sources prepared by other parties that the Company has deemed to be relevant and trustworthy. No representation or warranty, express or implied, is made by the Company as to the accuracy, completeness or verification of any information contained in this Presentation. The Company has not made any independent review of information based on public statistics or information from an independent third party regarding the market information that has been provided by such third party, the industry or general publications.*

*Statements in this Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors as they relate to events and depend on circumstances that will or may occur in the future, whether or not outside the control of the Company. No assurance is given that such forward-looking statements will prove to be correct. Past performance does not guarantee or predict future performance. Moreover, the Company does not – to the extent this is not required by law - undertake any obligation to review, update or confirm expectations or estimates or to release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this Presentation.*


*This Presentation as well as any other information provided by or on behalf of the Company in connection herewith shall be governed by Danish law. The courts of Denmark, with the District Court of Copenhagen as the first instance, shall have exclusive jurisdiction to settle any conflict or dispute arising out of or in connection with this Presentation or related matters.*

# Agenda

---

- Highlights from Q3, 2021
- Clinical Pipeline
- Financial Update Q3, 2021
- Outlook for 2021 – 2022
- Event Calendar
- Investment Highlights





**Close to 10 million  
people are dying  
from cancer every  
year**

**90% of cancer  
deaths are due to  
drug resistant  
cancer cells**

**The overall  
estimation of cancer  
patients who will  
respond to immuno-  
oncology agents is  
13%**



# Highlights from Q3, 2021

---

- August 25** US Patent and Trademark Office (USPTO) will grant the company's patent directed to the use of SCO-101
  - August 27** Approval from the German regulatory authorities to initiate clinical trials in Germany with SCO-101 in the PANTAX Ib study
  - September 2** Scandion Oncology and Alligator Bioscience announced the conclusion of their collaboration with a very positive outcome
  - September 6** Approval of the amendment of part 2 of CORIST Phase II study by the Danish Medicines Agency and the Ethics Committee
  - September 7** Scandion Oncology's Clinical Advisory Board strengthened by three additional members
  - September 8** Scandion Oncology provided novel information on its lead candidate drug SCO-101 and a focused clinical strategy with a clear path to registration at its Capital Markets Day
- 
- November 8** Read-out from PANTAX Phase Ib study postponed



# Scandion Oncology's Clinical Advisory Board

## - Strengthened by three additional members



**Richard L. Schilsky**  
MD, FACP, FSCT, FASCO

Former Executive Vice President and Chief Medical Officer of American Society of Clinical Oncology (ASCO) and past President of ASCO (2008-2009). Former Board member of Conquer Cancer, the ASCO Foundation



**Josep Tabernero**  
MD, PhD

Member of the Executive Board of the European Society for Medical Oncology (ESMO) and past ESMO President (2018 – 2019). Appointed as member of several Educational and Scientific Committees of ESMO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastro-intestinal, and ESMO-GI/WCGIC meetings



**Eric Van Cutsem**  
MD, PhD

President of the Belgian Foundation against Cancer. He co-founded ESMO GI/World Congress on Gastrointestinal Cancer, and is Chair of the meeting in Barcelona, Spain. He serves/served on the board or key committee of ESMO, ASCO, EORTC, ENET, ECCO, ESDO, and many others



**Thomas Seufferlein**  
MD

President of the German Cancer Society (DKG) and chairman of the committee for cancer prevention of the German Cancer Aid (DKH). Editor in Chief of the German Journal of Gastroenterology

# Scandion Oncology Capital Markets Day

---

- Focused clinical strategy with a clear path to market for SCO-101
- Positioning of market opportunities for SCO-101
- Novel insights on unique mode-of-action of SCO-101
- Recording can be found on Company homepage

# PANTAX Phase Ib Study Read-out Postponed

- Recruitment rate lower than anticipated
  1. More challenging to recruit patients than expected
  2. Clinical sites in Denmark opened slower than planned
  3. To internationalize the study, it expanded to Germany where the German Competent Authority required a staggered design
- Read-out now expected in Q2-Q3, 2022




“Disregarding the postponement, the study is performing as well as we could have hoped for”





# Clinical Pipeline

*Developing first-in-class medicines for personalized therapy targeting cancer drug resistance*

Program	Compound	Indication	Discovery / Pre-clinical	Phase I	Phase II	Phase III
CORIST	SCO-101	Colorectal cancer (RAS wt)				
PANTAX	SCO-101	Pancreatic cancer				
BIOMARKER DEVELOPMENT	SCO-101	Colorectal and Pancreatic cancer				

## Clinical Highlights Q3, 2021

- **PANTAX:** Approval to initiate clinical trials in Germany, on **August 27, 2021**
- **CORIST:** Approval for initiating part 2 of the CORIST Phase II study, on **September 6, 2021**
- **PANTAX:** Data read-out from PANTAX Ib study postponed, on **November 8, 2021**

## Upcoming Key Events in 2021-2022

- **CORIST:** Data read-out from CORIST part 2 is planned for **Q2-Q3, 2022**
- **PANTAX:** Data read-out from PANTAX Phase Ib is planned for **Q2-Q3, 2022**



# Financial Update Q3, 2021

# Financial Overview

- Net result and cost, overall in line with expectations
- Continued strengthening of the organization, according to plan
- Cost of the ongoing clinical studies CORIST and PANTAX, will further increase as the studies progress

Financial summary DKK '000	Q3		Ytd		Full year
	2021	2020	2021	2020	2020
Net sales	0	0	0	0	0
Other income	98	0	209	427	1,003
Staff cost	-7,104	-2,123	-16,467	-5,603	-9,396
Other expenses	-8,300	-2,788	-24,260	-8,533	-14,495
Financial items	-349	-46	-1,594	-394	2,235
Tax	346	1,066	5,500	3,032	4,384
<b>Net result</b>	<b>-15,309</b>	<b>-3,891</b>	<b>-36,612</b>	<b>-11,071</b>	<b>-16,269</b>
Earnings per share (DKK)	-0.48	-0.20	-1.14	-0.58	-0.83
<b>Cash position</b>	<b>117,360</b>	<b>7,505</b>	<b>117,360</b>	<b>7,505</b>	<b>5,814</b>



# Cash Position

Quarterly cash spend Q3 2021

14.1 MDKK

Cash position  
September 30, 2021

117.4 MDKK



Financing of the Company's  
operations until at least  
after 2022

Operating Expenses 2020 - Q3 2021



## Progression of clinical studies

Increase in operating expenses and cash spend will continue going forward driven by the planned progression of the clinical studies CORIST and PANTAX

# Expected Significant Events 2021 - 2022

Q2-Q3 2022



**CORIST**

Data read-out part 2 of Phase II study

Q2-Q3 2022








**PANTAX**

Data read-out Phase Ib study

Financing secured until  
at least after 2022

# Event Calendar

<b>November 18, 2021</b>		Dansk Aktionærforening, Investor week
<b>November 24, 2021</b>		ØU Investor Life Science Conference
<b>January 10-12, 2022</b>		Biotech Showcase at JPM
<b>January 20, 2022</b>		Redeye Fight Cancer Event
<b>January 25, 2022</b>		Swiss Nordic Bio 2022



# Why Invest in Scandion Oncology

## **We are first movers in cancer drug resistance**

- We are first-in-class, targeting a gigantic market

## **High medical need and yet also an established market**

- 10M cancer-related deaths annually
- SCO-101 has platform potential

## **De-risked clinical asset**

- Near proof-of-concept and value-inflection
- Pivotal trial within reach in 2023

## **Highly focused pipeline and clinical development**

- Focused early-stage pipeline for value creation
- Plethora of opportunities to broaden into other cancer indications

## **Run by seasoned leadership team**

- Leadership team with a clear track record
- Best in class CAB
- Strong and well-connected BoD

## **Multiple value inflection points over the next few years**

- PoC mCRC Phase II in Q2-Q3, 2022
- PDAC Phase Ib study read-out in Q2-Q3, 2022

## Q&A

### **Investor Relations:**

Bo Rode Hansen, President & CEO

Email: [ir@scandiononcology.com](mailto:ir@scandiononcology.com)

Phone: +45 38 10 20 17

**Sign up** to Scandion news on  
our website:

[www.scandiononcology.com](http://www.scandiononcology.com)